Inventor · disambiguated record
Augustus O. Okhamafe
Also filed as: OKHAMAFE AUGUSTUS · OKHAMAFE AUGUSTUS O
28 granted patents·22 pending applications·224 citations·filing 2004–2024
96Inventor score
Top patents by PatentIndex Score
50 records- 0196US7537923B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2008·Granted May 26, 2009·49 cites·9 claims
- 0294US8198242B2Variants of C-type natriuretic peptideWENDT DANIEL J·Filed 2010·Granted Jun 12, 2012·46 cites·17 claims
- 0394US7790433B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2009·Granted Sep 7, 2010·32 cites·6 claims
- 0492US10646550B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2018·Granted May 12, 2020·7 cites·13 claims
- 0590US8598121B2Variants of C-type natriuretic peptideWENDT DANIEL J·Filed 2012·Granted Dec 3, 2013·15 cites·14 claims
- 0689USRE43797EMethods of administering tetrahydrobiopterinOPPENHEIMER DANIEL I·Filed 2011·Granted Nov 6, 2012·12 cites·28 claims
- 0788USRE48267EVariants of C-type natriuretic peptideBIOMARIN PHARM INC·Filed 2017·Granted Oct 20, 2020·2 cites·76 claims
- 0888US7947681B2Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringBIOMARIN PHARM INC·Filed 2009·Granted May 24, 2011·10 cites·28 claims
- 0986US2024374688A1Use of C-Type Natriuretic Peptide Variants to Treat Skeletal DysplasiaBIOMARIN PHARM INC·Filed 2024·Application pending·0 cites
- 1085US8945564B2Antagonist anti-CD40 antibody pharmaceutical compositionsLU XIAOFENG·Filed 2007·Granted Feb 3, 2015·15 cites·37 claims
- 1182US12076372B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2023·Granted Sep 3, 2024·0 cites·16 claims
- 1281US11229687B2TPP-1 formulations and methods for treating CLN2 diseaseBIOMARIN PHARM INC·Filed 2020·Granted Jan 25, 2022·1 cites·18 claims
- 1381US9907834B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2016·Granted Mar 6, 2018·3 cites·8 claims
- 1480US11505790B2Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2019·Granted Nov 22, 2022·1 cites·14 claims
- 1580US10221408B2Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2016·Granted Mar 5, 2019·3 cites·18 claims
- 1679US9216178B2Dry blend formulation of tetrahydrobiopterinBIOMARIN PHARM INC·Filed 2012·Granted Dec 22, 2015·4 cites·4 claims
- 1778US8940513B2Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereofBIOMARIN PHARM INC·Filed 2014·Granted Jan 27, 2015·3 cites·20 claims
- 1878US8765437B2Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereofKOPPAKA VISH·Filed 2011·Granted Jul 1, 2014·6 cites·13 claims
- 1978US8614216B2Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid saltsOKHAMAFE AUGUSTUS O·Filed 2012·Granted Dec 24, 2013·8 cites·27 claims
- 2076US2024035013A1Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2022·Application pending·0 cites
- 2175US9567572B2Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereofBIOMARIN PHARM INC·Filed 2014·Granted Feb 14, 2017·2 cites·19 claims
- 2274US10758598B2TPP-1 formulations and methods for treating CLN2 diseaseBIOMARIN PHARM INC·Filed 2019·Granted Sep 1, 2020·1 cites·23 claims
- 2372US8202998B2Salts of benzimidazolyl pyridyl ethers and formulations thereofGULLAPALLI RAMPURNA·Filed 2007·Granted Jun 19, 2012·2 cites·3 claims
- 2469US11911446B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2020·Granted Feb 27, 2024·0 cites·27 claims
- 2569US11590204B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 2667US8324389B2Solid forms of a Raf kinase inhibitorHASHASH AHMAD·Filed 2008·Granted Dec 4, 2012·1 cites·9 claims
- 2766US8455662B2Formulations for benzimidazolyl pyridyl ethersHASHASH AHMAD·Filed 2007·Granted Jun 4, 2013·1 cites·39 claims
- 2865US2009181979A1Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical propertiesNOVARTIS VACCINES & DIAGNOSTIC·Filed 2009·Application pending·0 cites
- 2959US2013237543A1Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringBIOMARIN PHARM INC·Filed 2013·Application pending·0 cites
- 3059US2013338171A1Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical PropertiesCAI SHAOPEI·Filed 2013·Application pending·0 cites
- 3159US2017051033A1Variants of C-Type Natriuretic PeptideBIOMARIN PHARM INC·Filed 2016·Application pending·0 cites
- 3257US2005209247A1Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical propertiesCHIRON CORP·Filed 2004·Application pending·0 cites
- 3357US2005137399A1Methods for synthesizing quinolinone compoundsCHIRON CORP·Filed 2004·Application pending·0 cites
- 3456USRE46707EVariants of C-type natriuretic peptideBIOMARIN PHARM INC·Filed 2015·Granted Feb 13, 2018·0 cites·17 claims
- 3556US2012277434A1Methods for synthesizing quinolinone compoundsCAI SHAOPEI·Filed 2012·Application pending·0 cites
- 3656US2017000793A1Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringBIOMARIN PHARM INC·Filed 2016·Application pending·0 cites
- 3755US2013018058A1Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical propertiesCAI SHAOPEI·Filed 2011·Application pending·0 cites
- 3855US2019160070A1Dry blend formulation of tetrahydrobiopterinBIOMARIN PHARM INC·Filed 2019·Application pending·0 cites
- 3954US2016256553A1Variants of C-Type Natriuretic PeptideBIOMARIN PHARM INC·Filed 2015·Application pending·0 cites
- 4054US2011281880A1Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringOPPENHEIMER DANIEL I·Filed 2011·Application pending·0 cites
- 4152US10279015B2TPP-1 formulations and methods for treating CLN2 diseaseBIOMARIN PHARM INC·Filed 2016·Granted May 7, 2019·0 cites·25 claims
- 4252US2015110783A1Antagonist anti-cd40 antibody pharmaceutical compositionsNOVARTIS AG·Filed 2014·Application pending·0 cites
- 4352US2010278802A1Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2010·Application pending·0 cites
- 4451US2013039898A1Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2011·Application pending·0 cites
- 4550US8501785B2Salts of benzimidazolyl pyridyl ethers and formulations thereofGULLAPALLI RAMPURNA·Filed 2012·Granted Aug 6, 2013·0 cites·24 claims
- 4649US2011178097A1Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid saltsNOVARTIS AG·Filed 2006·Application pending·0 cites
- 4749US2008293738A1Formulation of QuinolinonesNOVARTIS AG·Filed 2006·Application pending·0 cites
- 4846US2016074406A1Dry blend formulation of tetrahydrobiopterinBIOMARIN PHARM INC·Filed 2015·Application pending·0 cites
- 4943US2012276200A1Formulations of quinolinonesCHOU JOYCE·Filed 2012·Application pending·0 cites
- 5036US2005250714A1Crystalline forms of 9-(S)-erythromycylamineLIN KANGWEN L·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Augustus O. Okhamafe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →